The most common cancer in men… and one of the most overlooked.

Prostate cancer is one of the most frequent tumors in men worldwide. It is estimated that 1 in 8 will develop it during their lifetime, and the risk increases significantly after the age of 50, especially in patients with a family history.

Despite its high prevalence, early diagnosis remains a challenge. Not due to a lack of medical studies or tools, but because many men continue to delay check-ups.

Tests that allow early detection

The main screenings for prostate cancer detection are:

• PSA (Prostate-Specific Antigen): a blood test that measures a protein produced by the prostate, which can be altered in different conditions.
• Digital rectal exam: a clinical examination that assesses the size, consistency, and possible irregularities of the prostate gland. 

Both tests are quick, accessible, and essential for detecting abnormalities at early stages.

The main problem is that prostate cancer often develops silently, without symptoms, for years. When signs such as difficulty urinating, blood in the urine, or pain appear, the disease may already be in more advanced stages. That is why waiting for symptoms is not a prevention strategy—it is a risk.

Early diagnosis changes the outlook

When detected early, prostate cancer has high survival rates and greater chances of less aggressive treatments. However, many patients still avoid regular check-ups due to fear, misinformation, or prejudice associated with the prostate exam.

In medical practice, this remains one of the main obstacles to early diagnosis. 

New technologies and less invasive treatments

For years, one of the greatest fears associated with prostate cancer was linked to traditional treatments, especially radical surgery, which can cause side effects such as urinary incontinence or erectile dysfunction. Today, technological advances have enabled more precise and less invasive approaches for selected cases.

Among them, focal laser ablation has emerged as an innovative alternative for localized, low- to moderate-risk tumors. Using precisely guided optical fibers, thermal energy selectively destroys tumor tissue while preserving much of the surrounding healthy tissue. This approach reduces the physical impact of treatment and better preserves urinary and sexual functions in selected patients.

Other technologies, such as HIFU (high-intensity focused ultrasound) and other minimally invasive focal procedures, can in certain cases offer results comparable to traditional treatments with fewer adverse effects. Not all patients are candidates for these therapies, but the paradigm shift is clear: treatments are becoming increasingly personalized, targeted, and conservative.

When cancer spreads beyond the prostate and no longer responds to hormone therapy, it is considered metastatic castration-resistant prostate cancer (mCRPC)—an advanced form of the disease in which the tumor continues to grow despite low testosterone levels. This marks a critical change in clinical management.

 In recent years, PSMA-targeted radionuclide therapy has revolutionized the management of mCRPC, offering new therapeutic opportunities beyond conventional treatments. Among emerging strategies, the use of lutetium-177 PSMA-617 stands out, with its impact on overall survival and sustained reduction of PSA levels widely supported by multiple clinical trials.

Talking about it is also prevention

 Prostate cancer can progress silently for a long time. That is why regular check-ups remain the most important tool for early detection. Today, simple diagnostic methods and increasingly precise treatments are available. But the first step remains the same: consulting on time. And remembering that undergoing check-ups does not mean assuming something is wrong—it means the opposite: being one step ahead.